2-Carboxybenzaldehyde

119-67-5

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enter₽prise that is market-oriented and realizes industrial development through R&D innovatio™n and technology transformation.

key word:

Pharmaceutical innovative

Category:

Intermediate

Product Description

Integrity, innovation, cooperation, sharing, win-win

The company integrates multiple resources and strives to build a large ↔health industry finance platform company integratin‌g pharmaceutical, intelligent medical, bio pharmaceutical R&D, indu≥strial production and sales.

The chemical reactions involved in the existing products include Foucault reaction, nitrλation reaction, sulfonation reaction, hydrogenation reaction", fluorination reaction, chlorination reaction, bromination reaction, diazotization reaction", format reaction, etc.

Related products

Sitagliptin Phosphate Monohydrate

Sitagliptin phosphate is a dipeptidyl peptidase-4 (DPP4) inhibitor developed b÷y Merck. In October 2006, Sitagliptin phosphate Ja↓nuvia was approved by FDA as the first DPP4 inhibitor for the treat±ment of type ⅱ diabetes mellitus. The characteristics of "this drug are that it can stimulate insulin secretion while reducing hunger without causing weigh→t gain. Hypoglycemia and edema will not occur, and it is suitable for diabetic patients with poφor blood glucose control and frequent hypoglycemia.

Sumatriptan Succinate

Medication for migraine

Vildagliptin

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterp→rise that is market-oriented and realizes industrial de™velopment through R&D innovation and technology transformation.

Ketoprofen

The non-steroidal anti-inflammatory drug ketoprofen is one of the most important products fβor the treatment of arthritis. It is well tolerated and has a low incidence of side e↔ffects

Pranlukast

Pranlukast, developed by Ono, is one of the three maj♦or leukotriene receptor antagonists. In clinical application, it has good therapeutic eff♣ect on atopic asthma and other types of bronchial asthma, and the market ₽prospect is huge. In the major category of asthma drugs, ☆leukotriene receptor antagonists have the fastest groεwing market share.

Avanafil

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterpri♥se that is market-oriented and realizes industrial development throπugh R&D innovation and technology transformation.

Donepezil HCL

Treatment of mild to moderate Alzheimer's syndrome. It is the secαond drug approved by FDA for Alzheimer's disease in the United Sta"tes. Its treatment reaches the target dose and has low toxic and sid×e effects. It has been widely recognized by our medical communi€ty, and good tolerance is its biggest advantage. In$ October 1999, Donepezil was launched in China under the trade name "Aricept", wh‌ich is the main chemical drug against Alzheimer's disease. At present, CFDA has approved a numbe↕r of domestic enterprises to produce donepezil preparations, the main dosage forms are tab≥lets, capsules, dispersive tablets, oral disintegrating tablets.

Almotriptan

Migraine medication for adolescents

Apixaban

English name Apixaban Trade name ELIQUIS, tablet: Apixaban (Eliquis, >Bristol-Myers Squibb/Pfizer), a direct oral factor Xa inhibitor, was approved for use in the 27♠ EU member states. The world's first drug approved to prevent venous thromboembolism (VTE) in adαult patients undergoing elective hip or knee replacement. From June 201®9 to June 2020, the annual sales of apixaban products overseas reached about $15γ.4 billion, with a year-on-year growth of nearly 32%, and the API consumption reached about 23<,960 kg, with a year-on-year growth of about 28%. Comp✘ared with its main competitor, Rivaroxaban, the drug's annual overs☆eas sales are about $4.5 billion higher.

Lenvatinib

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise tha¥t is market-oriented and realizes industrial development through R&D innovation and™ technology transformation.

Clofarabine

It is a nucleotide analogue developed by Bioenvision and manufacλtured by Genzyme. On December 29, 2004, it was approved by FDA for the treatment of refract≈ory or relapsed acute lymphoblastic leukemia (ALL) in child♥ren.

Upadacitinib(Scientific research)

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that is market-orient↓ed and realizes industrial development through R&D innovation and techno‍logy transformation.

Product Consulting

Our staff will contact you within 24 hours (working day↓s). If you need other services, E-mail: 2880705932@qq.com